第二代酪氨酸激酶抑制剂治疗失败后耐药慢性期慢性髓性白血病患者使用帕纳替尼的疗效与安全性
本文汇总PACE和OPTIC两项试验中,对既往至少一种第二代TKI耐药的慢性期慢性髓性白血病患者使用帕纳替尼的结局。24个月时,PACE组≤1% BCR::ABL1IS缓解率46%、PFS 68%、OS 85%,OPTIC组分别为57%、80%、91%。OPTIC基于缓解的剂量调整较PACE安全性改善且疗效相似。
要点
- 24个月时PACE组≤1% BCR::ABL1IS缓解率为46%,OPTIC组为57%。
- 24个月PFS在PACE组为68%、OPTIC组为80%,OS分别为85%和91%。
- 严重治疗中出现的不良事件PACE组63%、OPTIC组34%,严重动脉闭塞事件分别为18%和4%。
核心结论
- 帕纳替尼在既往第二代TKI治疗失败的慢性期慢性髓性白血病患者中显示出高缓解率和稳健的生存结局,包括携带T315I突变的患者。
- OPTIC中基于缓解的剂量调整较PACE安全性改善且疗效相似。
研究设计与样本
- 分析PACE(NCT01207440)和OPTIC(NCT02467270)两项试验中既往接受过至少一种第二代TKI治疗的慢性期慢性髓性白血病患者。
- PACE中帕纳替尼45 mg/天用于对既往TKI耐药或携带T315I的CML患者。
- OPTIC中对至少两种既往TKI耐药或携带T315I的CP-CML患者,接受45或30 mg/天,达到≤1% BCR::ABL1IS后减至15 mg/天,或持续接受15 mg/天。
- 分析人群为PACE中接受过至少一种第二代TKI的CP-CML患者(n=257)和OPTIC中45 mg起始剂量队列(n=93)。
主要发现
- 24个月时,PACE组≤1% BCR::ABL1IS缓解率为46%,PFS为68%,OS为85%。
- 24个月时,OPTIC组≤1% BCR::ABL1IS缓解率为57%,PFS为80%,OS为91%。
- 严重治疗中出现的不良事件发生率PACE组为63%、OPTIC组为34%;严重治疗中出现的动脉闭塞事件发生率PACE组为18%、OPTIC组为4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ponatinib, the only third-generation pan-BCR::ABL1 inhibitor with activity against all known BCR::ABL1 mutations including T315I, has demonstrated deep and durable responses in patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to prior second-generation (2G) TKI treatment. We present efficacy and safety outcomes from the Ponatinib Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and CML Evaluation (PACE) and Optimizing Ponatinib Treatment in CP-CML (OPTIC) trials for this patient population. PACE (NCT01207440) evaluated ponatinib 45 mg/day in CML patients with resistance to prior TKI or T315I. In OPTIC (NCT02467270), patients with CP-CML and resistance to ≥2 prior TKIs or T315I receiving 45 or 30 mg/day reduced their doses to 15 mg/day upon achieving ≤1% BCR::ABL1IS or received 15 mg/day continuously. Efficacy and safety outcomes from patients with CP-CML treated with ≥1 2G TKI (PACE, n = 257) and OPTIC (n = 93), 45-mg starting dose cohort, were analyzed for BCR::ABL1IS response rates, overall survival (OS), progression-free survival (PFS), and safety. By 24 months, the percentages of patients with ≤1% BCR::ABL1IS response, PFS, and OS were 46%, 68%, and 85%, respectively, in PACE and 57%, 80%, and 91%, respectively, in OPTIC. Serious treatment-emergent adverse events and serious treatment-emergent arterial occlusive event rates were 63% and 18% in PACE and 34% and 4% in OPTIC. Ponatinib shows high response rates and robust survival outcomes in patients whose disease failed prior to 2G TKIs, including patients with T315I mutation. The response-based dosing in OPTIC led to improved safety and similar efficacy outcomes compared with PACE.
引用
- Kantarjian HM, Jabbour E, Deininger M, et al. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022. PMID: 36054756. doi:10.1002/ajh.26686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。